Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: A GINECO prospective trial

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2808-2813

  Falandry, C ^a   Weber, B ^b   Savoye, A M ^c   Tinquaut, F ^d   Tredan, O ^e   Sevin, E ^f   Stefani, L ^g   Savinelli, F ^h   Atlassi, M ⁱ   Salvat, J ^j   Pujade Lauraine, E ^k   Freyer, G ^l  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE ALEXIS VAUTRIN   (France)

^c INSTITUT JEAN GODINOT   (France)

^d Hygee Center   (France)

^e CENTRE LÉON BÉRARD   (France)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g Centre Hospitalier de la Region d'Annecy   (France)

^h SAINT JOSEPH HOSPITAL   (France)

ⁱ CENTRE HOSPITALIER DU MANS   (France)

^j Hopitaux du Leman   (France)

^k HÔTEL DIEU   (France)

^l CENTRE HOSPITALIER LYON SUD   (France)

more..

Author keywords

Elderly; Geriatrics; Ovarian cancer; Prognostic factors

Indexed keywords

CARBOPLATIN;

ADVANCED CANCER; ADVANCED OVARIAN CANCER; AGED; ALBUMIN BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER PROGNOSIS; COMORBIDITY; DAILY LIFE ACTIVITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GERIATRIC PATIENT; GERIATRIC VULNERABILITY SCORE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INFECTION; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OVARY CANCER; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; POLYPHARMACY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTOPENIA; THROMBOSIS;

ELDERLY; GERIATRICS; OVARIAN CANCER; PROGNOSTIC FACTORS;

AGED; AGED, 80 AND OVER; CARBOPLATIN; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84887068031     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt360     Document Type: Article

References (20)

1. Oberaigner W, Minicozzi P, Bielska-Lasota M et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol 2012; 51: 441-453.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
3. Surveillance Epidemiology and End Results (SEER). 2013 http://seer.cancer.gov/statfacts/html/ovary.html. (4 February 2013, date last accessed).
4. Thigpen T, Brady MF, Omura GA et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993; 71: 606-614.
5. Freyer G, Geay JF, Touzet S et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 2005; 16: 1795-1800.
6. Trédan O, Geay JF, Touzet S et al. Carboplatin cyclophosphamide or carboplatin pacitaxel in elderly with advanced ovarian cancer? Analysis of two consecutive trials from the GINECO. Ann Oncol 2007; 18: 256-262.
7. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.
8. Zola P, Ferrero A. Is carboplatin-paclitaxel combination the standard treatment of elderly ovarian cancer patients? Ann Oncol 2007; 18: 213-214.
9. Hilpert F, du Bois A, Greimel ER et al. Feasibility, toxicity and quality of life of firstline chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer-a study by the AGO OVAR Germany. Ann Oncol 2006; 18: 282-287
10. Gerds TA, Schumacher M. Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biomed J 2006; 48: 1029-1040.
11. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112-3124.
12. Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology 2000; 14: 221-227.
13. Reuben DB, Rubenstein LV, Hirsch SH et al. Value of functional status as a predictor of mortality: results of a prospective study. Am J Med 1992; 93: 663-669.
14. Wang L, van Belle G, Kukull WB et al. Predictors of functional change: a longitudinal study of nondemented people aged 65 and older. J Am Geriatr Soc 2002; 50: 1525-1534.
15. Luck T, Luppa M, Wiese B et al. Prediction of incident dementia: impact of impairment in instrumental activities of daily living and mild cognitive impairment-results from the German Study on Ageing, Cognition, and Dementia in Primary Care Patients. Am J Geriatr Psychiatry 2012; 20: 943-954.
16. Regal P, Heatherington E. Baseline instrumental activities of daily living and incident dementia. J Am Geriatr Soc 2012; 60: 1189-1190.
17. Cretel E, Veen I, Pierres A et al. Immune profile of elderly patients admitted in a geriatric short care unit. Rev Med Interne 2011; 32: 275-282.
18. Blay JY, Chauvin F, Le Cesne A et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; x14: 636-643.
19. Ray-Coquard I, Cropet C, Van Glabbeke M et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas and lymphomas. Cancer Res 2009; 69: 5383-5391.
20. Tredan O, Ray-Coquard I, Chvetzoff G et al. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer 2011; 11: 1471-2407.